NR3C2 and type 2 diabetes mellitus: Additionally, the KDIGO guidelines suggest the use of a nonsteroidal mineralocorticoid receptor antagonist (finerenone) for adults with T2DM, an eGFR >25 mL/min per 1.73 m2, normal serum potassium levels, and UACR >30 mg/g despite the maximum tolerated dose of RASIs (2A) [63].